摘要:
The invention relates to compounds of the general formula (I) wherein R1 represents H, halogen, or OCF3; R2 and R3 each represents H or halogen; R4 represents C1-6-alkyl, C3-8-cycloalkyl, CF3, OCF3, F, Cl, OMe, or optionally substituted phenyl; V represents O, CH2O, OCF2, or O—C1-6-alkyl-O; and W represents CH2 or CH2CH2. A process for making such compounds, pharmaceutical compositions containing them, and methods of treatment of various conditions using them are also disclosed and claimed.
摘要:
Compounds of the general formula (I) wherein R1 represents halogen, R2 represent H or halogen, and R3 represents C3-8-cycloalkyl, C3-8-cycloalkenyl, or optionally substituted phenyl, pharmaceutical compositions containing such material, and methods of using such materials in the treatment of various diseases are disclosed and claimed.
摘要:
This invention relates to methods for treating cardiovascular disorders selected from heart failure, thromboembolic disorders, venous diseases, and fibriotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) wherein the several variables are as defined in the specification and claims.
摘要:
Compounds of the general formula (I) wherein R1 represents halogen, R2 and R3 represent H or halogen, and R4 represents C3-8-cycloalkyl or optionally substituted phenyl, pharamceutical compositions containing such materials, and methods of using such materials in the treatment of various diseases are disclosed and claimed.
摘要:
This invention relates to methods for treating cardiovascular disorders selected from heart failure, thromboembolic disorders, venous diseases, and fibriotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) wherein the several variables are as defined in the specification and claims.
摘要:
This invention relates to methods for treating cardiovascular disorder selected from heart failure, thromboembolic disorders, venous diseases, and fibrotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) in which the several variables are as defined in the specification and claims.
摘要:
This invention relates to methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis, comprising administering an effective amount of a compound of formula (I) in which the several variables are as defined in the specification and claims.
摘要:
The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.
摘要:
The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.
摘要:
Sulphonylbenzyl-substituted imidazoles can be prepared by first reacting imidazolylaldehydes with sulphonylbenzyl compounds and then oxidising or reducing the aldehyde function in the customary manner.The sulphonylbenzyl-substituted imidazoles can be used as active compounds in medicaments.